Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population

Rheumatology (United Kingdom)

Volumn 52, Issue 1, 2013, Pages 91-98

  Mercer, Louise K ^a   Davies, Rebecca ^a   Galloway, James B ^a   Low, Audrey ^a   Lunt, Mark ^a   Dixon, William G ^a   Watson, Kath D ^a   Symmons, Deborah P M ^a   Hyrich, Kimme L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cancer; Lymphoma; Rheumatoid arthritis; Standardized incidence ratio

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ADULT; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; POISSON DISTRIBUTION; POPULATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; RHEUMATOID ARTHRITIS; SMOKING; STANDARDIZED INCIDENCE RATIO; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; RISK;

EID: 84871127807     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes350     Document Type: Article

References (36)

1. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691-6.
2. Smitten AL, Simon TA, Hochberg MC et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10: R45.
3. Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
4. Flossmann E, Rothwell PM; British Doctors Aspirin Trial the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369: 1603-13.
5. Luqmani R, Hennell S, Estrach C et al. British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology 2006;45: 1167-9.
6. Luqmani R, Hennell S, Estrach C et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology 2009;48:436-9.
7. Hyrich KL, Watson KD, Isenberg DA et al. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology 2008;47:1441-3.
8. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986; 25:206-9.
9. BSRBR. Event of Special Interest (ESI) Report; Malignancy. http://www.medicine.manchester.ac.uk/images/File/ESI-07-malig-form.pdf. (15 February 2012, date last accessed).
10. Office for National Statistics. Cancer statistics: registrations series MB1. http://ons.gov.uk/ons/datasets-and-tables/search/index.html?newquery=mb1 (1 January 2010, date last accessed).
11. World Health Organization. International statistical classification of diseases and related health problems, 10th revision. http://apps.who.int/classifications/apps/icd/icd10online/ (12 June 2010, date last accessed).
12. Office for National Statistics. Cancer statistics: registrations series MB1 - No. 39, 2008. http://ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-198611 (11 July 2011, date last accessed).
13. Mercer LK, Green AC, Galloway JB et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012;71:869-74.
14. Abasolo L, Judez E, Descalzo MA et al. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2008;37:388-97.
15. Chen YJ, Chang YT, Wang CB et al. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum 2011;63:352-8.
16. Askling J, Fored CM, Brandt L et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6.
17. Jensen P, Hansen S, Moller B et al. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Transplant Proc 1999;31: 1120.
18. Glover MT, Deeks JJ, Raftery MJ et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997;349: 398.
19. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-8.
20. Fairchild WV, Spence CR, Solomon HD et al. The incidence of bladder cancer after cyclophosphamide therapy. J Urol 1979;122:163-4.
21. Radis CD, Kahl LE, Baker GL et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995; 38:1120-7.
22. Mattey DL, Thomson W, Ollier WE et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum 2007;56:1408-16.
23. Parikh-Patel A, White RH. Risk of cancer among rheumatoid arthritis patients in California. Cancer Cause Control 2009;20:1001-10.
24. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40:1580-6.
25. Gridley G, McLaughlin JK, Ekbom A et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
26. Mellemkjaer L, Linet MS, Gridley G et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A: 1753-7.
27. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Cause Control 2002;13:427-34.
28. Salinas CA, Kwon EM, Fitz Gerald LM et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 2010;172: 578-90.
29. Prizment AE, Folsom AR, Anderson KE. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2010;19:435-42.
30. Murad AS, Down L, Davey SG et al. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int J Cancer 2011;128:1442-8.
31. Brasky TM, Velicer CM, Kristal AR et al. Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev 2010;19:3185-8.
32. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008;100:1439-47.
33. Thomas E, Brewster DH, Black RJ et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
34. Office for National Statistics. Summary quality report for cancer registration statistics. http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Cancer (1 March 2012, date last accessed).
35. Symmons D, Harrison B. Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. I. Risk factors for the development of inflammatory polyarthritis and rheumatoid arthritis. Rheumatology 2000;39:835-43.
36. Office for National Statistics. Cancer statistics: registrations series MB1 - No. 39, 2008. http://ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-198611 (11 July 2011, date last accessed).